 Timothy Bernard
Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 45 | 2023 | 1120 | 5.220 |
Why?
| | Brain Ischemia | 22 | 2022 | 338 | 3.400 |
Why?
| | Cerebral Arterial Diseases | 13 | 2024 | 47 | 2.610 |
Why?
| | Fibrinolytic Agents | 6 | 2020 | 270 | 1.140 |
Why?
| | Thrombolytic Therapy | 7 | 2015 | 142 | 1.110 |
Why?
| | Magnetic Resonance Angiography | 5 | 2024 | 240 | 0.890 |
Why?
| | Pediatrics | 10 | 2019 | 1101 | 0.880 |
Why?
| | Thrombophilia | 5 | 2011 | 83 | 0.820 |
Why?
| | Moyamoya Disease | 5 | 2024 | 20 | 0.800 |
Why?
| | Child | 59 | 2025 | 21935 | 0.740 |
Why?
| | Thromboembolism | 3 | 2013 | 119 | 0.680 |
Why?
| | Cerebral Arteries | 3 | 2024 | 59 | 0.650 |
Why?
| | Disease Management | 4 | 2017 | 628 | 0.610 |
Why?
| | Intracranial Arterial Diseases | 2 | 2024 | 8 | 0.610 |
Why?
| | Arteries | 4 | 2017 | 269 | 0.610 |
Why?
| | Vertebral Artery Dissection | 4 | 2022 | 24 | 0.570 |
Why?
| | Child, Preschool | 35 | 2025 | 11074 | 0.550 |
Why?
| | Cerebrovascular Disorders | 2 | 2022 | 96 | 0.540 |
Why?
| | Hospitals, Pediatric | 2 | 2020 | 508 | 0.470 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2012 | 82 | 0.460 |
Why?
| | Tissue Plasminogen Activator | 2 | 2014 | 224 | 0.450 |
Why?
| | Anticoagulants | 6 | 2020 | 664 | 0.420 |
Why?
| | Adolescent | 35 | 2025 | 21513 | 0.420 |
Why?
| | Tertiary Care Centers | 1 | 2014 | 160 | 0.410 |
Why?
| | Recurrence | 9 | 2022 | 1060 | 0.410 |
Why?
| | Infant | 26 | 2025 | 9465 | 0.390 |
Why?
| | Migraine with Aura | 1 | 2012 | 6 | 0.380 |
Why?
| | Neuroimaging | 4 | 2024 | 259 | 0.380 |
Why?
| | Cerebral Revascularization | 3 | 2024 | 19 | 0.370 |
Why?
| | Edema | 1 | 2012 | 130 | 0.360 |
Why?
| | Arterial Occlusive Diseases | 2 | 2010 | 83 | 0.350 |
Why?
| | Venous Thrombosis | 2 | 2016 | 190 | 0.350 |
Why?
| | Humans | 66 | 2025 | 137585 | 0.350 |
Why?
| | Risk Factors | 15 | 2020 | 10388 | 0.350 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 173 | 0.340 |
Why?
| | Prognosis | 9 | 2020 | 4030 | 0.340 |
Why?
| | Disease Progression | 2 | 2018 | 2757 | 0.340 |
Why?
| | Sinus Thrombosis, Intracranial | 3 | 2021 | 21 | 0.330 |
Why?
| | Infant, Newborn | 17 | 2025 | 6079 | 0.330 |
Why?
| | Venous Thromboembolism | 2 | 2014 | 316 | 0.320 |
Why?
| | Vertebral Artery | 2 | 2022 | 26 | 0.320 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 1050 | 0.310 |
Why?
| | Quality of Health Care | 1 | 2014 | 642 | 0.310 |
Why?
| | Thrombosis | 1 | 2012 | 371 | 0.300 |
Why?
| | Brain Infarction | 2 | 2018 | 23 | 0.270 |
Why?
| | Overweight | 1 | 2012 | 558 | 0.270 |
Why?
| | Cerebral Angiography | 5 | 2024 | 109 | 0.270 |
Why?
| | Biomarkers | 5 | 2016 | 4149 | 0.260 |
Why?
| | Neurology | 1 | 2008 | 113 | 0.260 |
Why?
| | Cohort Studies | 10 | 2021 | 5742 | 0.250 |
Why?
| | Age of Onset | 6 | 2020 | 518 | 0.250 |
Why?
| | Research Design | 1 | 2012 | 1139 | 0.250 |
Why?
| | Prostheses and Implants | 1 | 2007 | 143 | 0.250 |
Why?
| | Retrospective Studies | 17 | 2024 | 15657 | 0.250 |
Why?
| | Intracranial Aneurysm | 3 | 2022 | 97 | 0.230 |
Why?
| | Embolization, Therapeutic | 1 | 2007 | 229 | 0.230 |
Why?
| | Male | 33 | 2025 | 67762 | 0.230 |
Why?
| | Female | 33 | 2025 | 73304 | 0.210 |
Why?
| | Adenosine Deaminase | 1 | 2023 | 36 | 0.200 |
Why?
| | Age Factors | 7 | 2020 | 3295 | 0.200 |
Why?
| | Infarction, Middle Cerebral Artery | 2 | 2022 | 40 | 0.200 |
Why?
| | Mydriasis | 1 | 2022 | 10 | 0.190 |
Why?
| | Multicenter Studies as Topic | 2 | 2014 | 310 | 0.190 |
Why?
| | Treatment Outcome | 11 | 2024 | 10811 | 0.180 |
Why?
| | Anesthetics | 1 | 2022 | 81 | 0.180 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2023 | 382 | 0.180 |
Why?
| | C-Reactive Protein | 2 | 2016 | 410 | 0.180 |
Why?
| | Guidelines as Topic | 2 | 2020 | 275 | 0.170 |
Why?
| | Hospitals, Special | 1 | 2020 | 9 | 0.170 |
Why?
| | Incidence | 6 | 2021 | 2804 | 0.170 |
Why?
| | Athletic Injuries | 1 | 2007 | 529 | 0.170 |
Why?
| | Reproducibility of Results | 5 | 2016 | 3284 | 0.170 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2021 | 93 | 0.160 |
Why?
| | Follow-Up Studies | 5 | 2020 | 5131 | 0.160 |
Why?
| | Cerebral Infarction | 2 | 2020 | 44 | 0.160 |
Why?
| | Mechanical Thrombolysis | 1 | 2019 | 4 | 0.150 |
Why?
| | Colorado | 5 | 2017 | 4565 | 0.150 |
Why?
| | Epilepsy | 1 | 2023 | 333 | 0.150 |
Why?
| | Streptococcal Infections | 1 | 2021 | 151 | 0.150 |
Why?
| | Obesity | 1 | 2012 | 2992 | 0.150 |
Why?
| | Inflammation | 1 | 2009 | 2837 | 0.150 |
Why?
| | Sinusitis | 1 | 2021 | 221 | 0.150 |
Why?
| | Carotid Stenosis | 2 | 2018 | 91 | 0.150 |
Why?
| | Intracranial Thrombosis | 2 | 2016 | 17 | 0.140 |
Why?
| | Program Development | 1 | 2020 | 364 | 0.140 |
Why?
| | Prospective Studies | 7 | 2025 | 7604 | 0.140 |
Why?
| | Smith-Magenis Syndrome | 1 | 2017 | 2 | 0.140 |
Why?
| | Recovery of Function | 2 | 2020 | 653 | 0.140 |
Why?
| | Diagnostic Imaging | 3 | 2009 | 332 | 0.130 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 5778 | 0.130 |
Why?
| | Serum Amyloid A Protein | 1 | 2016 | 33 | 0.130 |
Why?
| | Observer Variation | 3 | 2011 | 343 | 0.130 |
Why?
| | Hippocampus | 2 | 2018 | 895 | 0.130 |
Why?
| | Cerebral Veins | 1 | 2016 | 16 | 0.120 |
Why?
| | Peroxidase | 1 | 2016 | 175 | 0.120 |
Why?
| | Cavernous Sinus Thrombosis | 1 | 2015 | 9 | 0.120 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 2031 | 0.120 |
Why?
| | Encephalitis | 1 | 2017 | 136 | 0.120 |
Why?
| | Neurosurgical Procedures | 1 | 2017 | 197 | 0.120 |
Why?
| | Prevalence | 4 | 2022 | 2734 | 0.110 |
Why?
| | Alagille Syndrome | 1 | 2014 | 33 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 1 | 2023 | 2426 | 0.110 |
Why?
| | Registries | 4 | 2020 | 2035 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 6 | 2022 | 3566 | 0.110 |
Why?
| | National Institutes of Health (U.S.) | 2 | 2011 | 128 | 0.110 |
Why?
| | Hyperhomocysteinemia | 1 | 2013 | 27 | 0.100 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2013 | 36 | 0.100 |
Why?
| | Apoprotein(a) | 1 | 2013 | 7 | 0.100 |
Why?
| | Proteomics | 2 | 2023 | 1111 | 0.100 |
Why?
| | Health Expenditures | 1 | 2014 | 189 | 0.100 |
Why?
| | ADAM Proteins | 1 | 2012 | 61 | 0.100 |
Why?
| | Quality Control | 1 | 2012 | 172 | 0.100 |
Why?
| | Lipoprotein(a) | 1 | 2013 | 67 | 0.100 |
Why?
| | Vascular Diseases | 1 | 2014 | 243 | 0.090 |
Why?
| | Mass Spectrometry | 1 | 2014 | 739 | 0.090 |
Why?
| | Heart Diseases | 1 | 2014 | 346 | 0.090 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2016 | 1242 | 0.090 |
Why?
| | Middle Cerebral Artery | 2 | 2022 | 53 | 0.090 |
Why?
| | Anemia, Sickle Cell | 2 | 2011 | 270 | 0.080 |
Why?
| | Critical Care | 1 | 2016 | 601 | 0.080 |
Why?
| | Delphi Technique | 1 | 2011 | 280 | 0.080 |
Why?
| | Health Surveys | 1 | 2012 | 514 | 0.080 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2828 | 0.080 |
Why?
| | Proteome | 1 | 2014 | 472 | 0.080 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2010 | 21 | 0.080 |
Why?
| | Asphyxia Neonatorum | 1 | 2010 | 17 | 0.080 |
Why?
| | Cognition | 1 | 2017 | 1153 | 0.080 |
Why?
| | Factor VIII | 1 | 2009 | 98 | 0.080 |
Why?
| | Germany | 1 | 2009 | 121 | 0.080 |
Why?
| | Consensus | 1 | 2011 | 683 | 0.070 |
Why?
| | Acute Disease | 2 | 2009 | 1007 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1483 | 0.070 |
Why?
| | Brain | 3 | 2024 | 2668 | 0.070 |
Why?
| | Cross-Sectional Studies | 2 | 2016 | 5472 | 0.070 |
Why?
| | Soccer | 1 | 2007 | 42 | 0.070 |
Why?
| | Developmental Disabilities | 1 | 2010 | 263 | 0.070 |
Why?
| | Seizures | 2 | 2023 | 426 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2012 | 1477 | 0.060 |
Why?
| | Time Factors | 3 | 2017 | 6828 | 0.060 |
Why?
| | Football | 1 | 2007 | 85 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 740 | 0.060 |
Why?
| | Case-Control Studies | 3 | 2025 | 3556 | 0.060 |
Why?
| | Secondary Prevention | 1 | 2007 | 233 | 0.060 |
Why?
| | Parents | 1 | 2014 | 1347 | 0.060 |
Why?
| | Testosterone | 1 | 2009 | 409 | 0.060 |
Why?
| | Cognition Disorders | 1 | 2010 | 496 | 0.060 |
Why?
| | Physical Therapy Modalities | 1 | 2008 | 308 | 0.060 |
Why?
| | Neuromyelitis Optica | 1 | 2006 | 132 | 0.060 |
Why?
| | Pandemics | 2 | 2025 | 1639 | 0.060 |
Why?
| | Brain Injuries | 1 | 2010 | 494 | 0.060 |
Why?
| | Young Adult | 6 | 2024 | 13209 | 0.060 |
Why?
| | Heart Defects, Congenital | 1 | 2011 | 842 | 0.050 |
Why?
| | Australia | 1 | 2025 | 315 | 0.050 |
Why?
| | Algorithms | 1 | 2011 | 1704 | 0.050 |
Why?
| | United States | 6 | 2019 | 14841 | 0.050 |
Why?
| | Hereditary Autoinflammatory Diseases | 1 | 2023 | 7 | 0.050 |
Why?
| | Global Health | 2 | 2020 | 386 | 0.050 |
Why?
| | Heterozygote | 1 | 2023 | 293 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2006 | 893 | 0.050 |
Why?
| | Streptococcus anginosus | 1 | 2021 | 9 | 0.040 |
Why?
| | Muscle, Smooth | 1 | 2022 | 155 | 0.040 |
Why?
| | Syndrome | 1 | 2022 | 358 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2025 | 625 | 0.040 |
Why?
| | Mutation | 1 | 2012 | 3958 | 0.040 |
Why?
| | Vasculitis, Central Nervous System | 1 | 2020 | 14 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 1587 | 0.040 |
Why?
| | Genetic Testing | 1 | 2023 | 460 | 0.040 |
Why?
| | Adult | 5 | 2023 | 37929 | 0.040 |
Why?
| | Carotid Artery Diseases | 1 | 2019 | 64 | 0.040 |
Why?
| | Association | 1 | 2019 | 12 | 0.040 |
Why?
| | Neck | 1 | 2019 | 101 | 0.040 |
Why?
| | Headache | 1 | 2020 | 147 | 0.040 |
Why?
| | Anterior Cerebral Artery | 1 | 2018 | 5 | 0.040 |
Why?
| | Posterior Cerebral Artery | 1 | 2018 | 7 | 0.040 |
Why?
| | Autoantibodies | 1 | 2006 | 1496 | 0.040 |
Why?
| | Carotid Artery, Internal | 1 | 2018 | 42 | 0.040 |
Why?
| | Risk Assessment | 1 | 2007 | 3457 | 0.030 |
Why?
| | Gastroepiploic Artery | 1 | 2017 | 4 | 0.030 |
Why?
| | Computed Tomography Angiography | 1 | 2018 | 129 | 0.030 |
Why?
| | American Heart Association | 1 | 2019 | 306 | 0.030 |
Why?
| | Nervous System Diseases | 1 | 2020 | 266 | 0.030 |
Why?
| | Memory Disorders | 1 | 2017 | 164 | 0.030 |
Why?
| | Receptors, GABA-A | 1 | 2017 | 142 | 0.030 |
Why?
| | Odds Ratio | 2 | 2009 | 1070 | 0.030 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2017 | 198 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 322 | 0.030 |
Why?
| | Long-Term Potentiation | 1 | 2017 | 198 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2019 | 580 | 0.030 |
Why?
| | Intellectual Disability | 1 | 2017 | 165 | 0.030 |
Why?
| | Neuronal Plasticity | 1 | 2017 | 290 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 3196 | 0.030 |
Why?
| | Electroencephalography | 1 | 2017 | 423 | 0.030 |
Why?
| | Radiography | 1 | 2016 | 822 | 0.030 |
Why?
| | Canada | 1 | 2014 | 418 | 0.030 |
Why?
| | ADAMTS13 Protein | 1 | 2012 | 7 | 0.030 |
Why?
| | Forecasting | 1 | 2014 | 389 | 0.020 |
Why?
| | Survival Rate | 1 | 2017 | 1972 | 0.020 |
Why?
| | Cost of Illness | 1 | 2014 | 308 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2024 | 2654 | 0.020 |
Why?
| | Population | 1 | 2011 | 35 | 0.020 |
Why?
| | Ischemia | 1 | 2014 | 409 | 0.020 |
Why?
| | Fibrinolysis | 1 | 2013 | 146 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 2892 | 0.020 |
Why?
| | Constriction, Pathologic | 1 | 2011 | 245 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2013 | 660 | 0.020 |
Why?
| | Risk | 1 | 2013 | 912 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2011 | 363 | 0.020 |
Why?
| | Hematocrit | 1 | 2009 | 96 | 0.020 |
Why?
| | Observation | 1 | 2009 | 50 | 0.020 |
Why?
| | Population Surveillance | 1 | 2012 | 482 | 0.020 |
Why?
| | Intracranial Hemorrhages | 1 | 2009 | 85 | 0.020 |
Why?
| | International Cooperation | 1 | 2009 | 198 | 0.020 |
Why?
| | Chronic Disease | 1 | 2014 | 1793 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1916 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2009 | 242 | 0.020 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2011 | 463 | 0.020 |
Why?
| | Cholesterol | 1 | 2009 | 410 | 0.020 |
Why?
| | Hospitalization | 1 | 2017 | 2199 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 5757 | 0.020 |
Why?
| | Methylprednisolone | 1 | 2006 | 86 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2009 | 1509 | 0.020 |
Why?
| | Pilot Projects | 1 | 2011 | 1710 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2010 | 1023 | 0.010 |
Why?
| | Respiratory Tract Infections | 1 | 2009 | 390 | 0.010 |
Why?
| | Electronic Health Records | 1 | 2011 | 1069 | 0.010 |
Why?
| | Sex Factors | 1 | 2009 | 2071 | 0.010 |
Why?
| | Students | 1 | 2009 | 622 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 2006 | 496 | 0.010 |
Why?
| | Animals | 2 | 2017 | 36940 | 0.010 |
Why?
| | Mice | 1 | 2017 | 17787 | 0.010 |
Why?
| | Aged | 1 | 2019 | 23961 | 0.010 |
Why?
| | Middle Aged | 1 | 2019 | 33479 | 0.010 |
Why?
|
|
Bernard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|